

REMARKS & ARGUMENTS

Claims 34 and 36 stand rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to make and or use the invention. Applicants traverse the rejection and respectfully request withdrawal of the same.

The Examiner has suggested that Applicants remove the term “pharmaceutical” from the claim 34. To expedite prosecution, Applicants have amended claim 34 to remove the term.

The Examiner has suggested that Applicants cancel claim 36. Applicants have shown, however, that representative compounds described in Examples 1 to 109 inhibited human endothelial cell migration. Angiogenesis is the fundamental process by which new blood vessels are formed. As described in the application, many diseases are driven by persistent unregulated angiogenesis. For example, ocular neovascularization has been implicated as the most common cause of blindness. In certain existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous, bleed, and cause blindness. Growth and metastasis of solid tumors are also angiogenesis-dependent (Folkman, J., *Cancer Research*, **46**: 467-473 (1986), Folkman, J., *Journal of the National Cancer Institute*, **82**: 4-6 (1989)). Therefore, since Applicants have demonstrated the ability of the invented compounds to inhibit cell migration, thereby preventing angiogenesis, and since the diseases recited in claim 36 are known to be “angiogenic diseases” Applicants maintain that claim 36 is enabled. None-the-less, in order to expedite prosecution, Applicants cancel claim 36.


Applicants have added new claims 37 and 38 as the Examiner suggested.

ACTION REQUESTED

Allowance of claims 1-33, 38, 39, 40, and 41 is respectfully requested. If the Examiner has any concerns he is invite to contact me directly at telephone number below.

Respectfully submitted,
Haviv, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7956
Facsimile: (847) 938-2623



Jolanna M. Corbin
Registration No. 51,582
Attorney for Applicants